IRIS
PETRONINI, Pier Giorgio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.792
AS - Asia 10.247
EU - Europa 7.732
SA - Sud America 1.344
AF - Africa 509
Continente sconosciuto - Info sul continente non disponibili 335
OC - Oceania 11
Totale 32.970
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.498
SG - Singapore 3.582
CN - Cina 2.937
IT - Italia 1.634
VN - Vietnam 1.592
FI - Finlandia 1.151
IE - Irlanda 1.136
BR - Brasile 1.065
SE - Svezia 990
DE - Germania 800
HK - Hong Kong 712
UA - Ucraina 546
FR - Francia 358
ZA - Sudafrica 328
NL - Olanda 301
TR - Turchia 296
BD - Bangladesh 295
GB - Regno Unito 212
IN - India 208
CA - Canada 183
RU - Federazione Russa 161
AR - Argentina 111
AT - Austria 98
BE - Belgio 88
KR - Corea 78
CI - Costa d'Avorio 72
JP - Giappone 70
MX - Messico 63
PL - Polonia 60
IQ - Iraq 59
ID - Indonesia 52
EC - Ecuador 49
PK - Pakistan 44
ES - Italia 43
CO - Colombia 40
CZ - Repubblica Ceca 38
PH - Filippine 38
TH - Thailandia 35
VE - Venezuela 30
IR - Iran 24
LT - Lituania 24
MA - Marocco 24
UZ - Uzbekistan 24
EG - Egitto 22
JO - Giordania 22
SA - Arabia Saudita 20
TN - Tunisia 16
TW - Taiwan 16
KE - Kenya 15
PS - Palestinian Territory 15
AE - Emirati Arabi Uniti 13
EE - Estonia 12
JM - Giamaica 12
PY - Paraguay 12
AZ - Azerbaigian 11
IL - Israele 11
MY - Malesia 11
CL - Cile 10
KZ - Kazakistan 10
PE - Perù 10
RO - Romania 10
AL - Albania 9
DZ - Algeria 9
HU - Ungheria 9
LB - Libano 9
NP - Nepal 9
OM - Oman 9
UY - Uruguay 9
CR - Costa Rica 8
AU - Australia 7
BO - Bolivia 7
LU - Lussemburgo 7
QA - Qatar 7
SY - Repubblica araba siriana 7
CH - Svizzera 6
ET - Etiopia 6
GE - Georgia 6
GT - Guatemala 6
KG - Kirghizistan 6
MD - Moldavia 6
HN - Honduras 5
PA - Panama 5
PT - Portogallo 5
DO - Repubblica Dominicana 4
LV - Lettonia 4
NZ - Nuova Zelanda 4
AM - Armenia 3
BG - Bulgaria 3
BW - Botswana 3
EU - Europa 3
HR - Croazia 3
LK - Sri Lanka 3
NO - Norvegia 3
SI - Slovenia 3
SN - Senegal 3
TT - Trinidad e Tobago 3
AO - Angola 2
BB - Barbados 2
BH - Bahrain 2
BY - Bielorussia 2
Totale 32.604
Salva come PNG Salva come JPEG
Città #
Singapore 1.845
Ashburn 1.342
Dublin 1.133
San Jose 1.126
Chandler 1.092
Dallas 1.025
Santa Clara 710
Beijing 673
Hong Kong 662
Jacksonville 615
Ann Arbor 597
Parma 486
Ho Chi Minh City 473
Dearborn 447
Council Bluffs 427
Boardman 372
Hanoi 358
New York 326
Johannesburg 313
Los Angeles 281
Nanjing 264
Izmir 244
Shanghai 235
Princeton 210
Munich 208
Lauterbourg 207
San Mateo 178
Hefei 166
Wilmington 138
Bremen 128
Milan 125
Chicago 123
Helsinki 115
São Paulo 108
Buffalo 98
Nanchang 98
Toronto 97
Kunming 93
Shenyang 92
Hebei 85
Moscow 84
Vienna 83
Jinan 82
Haiphong 76
Abidjan 72
Woodbridge 72
Brussels 71
Tianjin 66
Bologna 64
Frankfurt am Main 64
Da Nang 63
Rome 61
Columbus 59
Des Moines 58
Houston 56
Seattle 56
Seoul 53
Guangzhou 52
Tokyo 51
Marseille 50
Changsha 49
Turku 49
The Dalles 48
Jiaxing 46
Modena 44
Warsaw 42
Brooklyn 41
London 40
Pune 40
Amsterdam 36
Norwalk 35
Rio de Janeiro 35
Stockholm 33
Düsseldorf 32
Jakarta 32
Denver 31
Montreal 30
Phoenix 29
Orem 28
Reggio Emilia 28
San Francisco 28
Belo Horizonte 26
Hangzhou 26
Manchester 26
Brasília 25
Biên Hòa 24
Redmond 24
Augusta 23
Chennai 23
Fremont 23
Tashkent 23
Zhengzhou 23
Atlanta 22
Boston 22
Hải Dương 22
Baghdad 21
Dhaka 21
Levanto 21
New Delhi 21
Amman 20
Totale 19.820
Salva come PNG Salva come JPEG
Nome #
Balancing reactivity and antitumor activity: heteroarylthioacetamide derivatives as potent and time-dependent inhibitors of EGFR 353
A New ABCB1 Inhibitor Enhances the Anticancer Effect of Doxorubicin in Both In Vitro and In Vivo Models of NSCLC 299
Targeting metabolic adaptive responses induced by glucose starvation inhibits cell proliferation and enhances cell death in osimertinib-resistant non-small cell lung cancer (NSCLC) cell lines 285
Efficacy of the cdk4/6 dual inhibitor abemaciclib in egfr-mutated nsclc cell lines with different resistance mechanisms to osimertinib 254
PD-L1 overexpression induces STAT signaling and promotes the secretion of pro-angiogenic cytokines in non-small cell lung cancer (NSCLC) 254
Targeting glucosylceramide synthase induces antiproliferative and proapoptotic effects in osimertinib-resistant NSCLC cell models 249
Polymeric films loaded with cisplatin for malignant pleural mesothelioma: a pharmacokinetic study in an ovine model 249
Combined hyaluronate-based films loaded with pemetrexed and cisplatin for the treatment of malignant pleural mesothelioma: Preliminary evaluation in an orthotopic tumor recurrence model 239
CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells 222
Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines. 220
Irreversible Inhibition of Epidermal Growth Factor Receptor Activity by 3-Aminopropanamides. 217
Pemetrexed enhances membrane PD-L1 expression and potentiates T cell-mediated cytotoxicity by anti-PD-L1 antibody therapy in non-small-cell lung cancer 215
Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells. 213
CDK4/6 Inhibition Enhances the Efficacy of Standard Chemotherapy Treatment in Malignant Pleural Mesothelioma Cells 212
5-Benzylidene-hydantoins as new EGFR inhibitors with antiproliferative activity 211
Afatinib therapy in case of EGFR G724S emergence as resistance mechanism to osimertinib 211
Allotrapianto di polmone sinistro nel coniglio.Modello sperimentale per lo studio della conservazione del polmone. 211
Targeting PI3K somatic mutations reduces invasion and EMT in squamous cell carcinoma of the lung 208
A sulfonyl fluoride derivative inhibits EGFR L858R/T790M/C797S by covalent modification of the catalytic lysine 208
Dual inhibition of CDK4/6 and PI3K/AKT/mTOR signaling impairs energy metabolism in MPM cancer cells 206
5-Benzylidene-hydantoins: synthesis and antiproliferative activity on A549 lung cancer cell line 206
Effect of inducible FHIT and p53 expression in the Calu-1 lung cancer cell line 200
Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC 200
Immunomodulatory effects of antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma models: Impact on following anti-PD-1 treatments 197
Novel Irreversible Epidermal Growth Factor Receptor Inhibitors by Chemical Modulation of the Cysteine-Trap Portion 196
Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance 196
Characterization of gefitinib uptake in NSCLC cell lines 194
A three-fold novel nanosystem made by SiC/SiO2 core/shell nanowires functionalized with magnetic nanoparticles and substituted porphyrin for nanomedicine applications 192
Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines 192
Induction of BGT-1 and amino acid system A transport activities in endothelial cells exposed to hyperosmolarity 191
A Photoactive Supramolecular Complex Targeting PD-L1 Reveals a Weak Correlation between Photoactivation Efficiency and Receptor Expression Levels in Non-Small-Cell Lung Cancer Tumor Models 188
Creatine as a compatible osmolyte in muscle cells exposed to hypertonic stress 188
Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism. 187
Galectin-1 suppression delineates a new strategy to inhibit myeloma-induced angiogenesis and tumoral growth in vivo 187
Isolation and Characterization of Circulating Tumor Cells in Squamous Cell Carcinoma of the Lung Using a Non-EpCAM-Based Capture Method 186
Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation 185
Anti-proliferative effect of letrozole and sorafenib in MCF-7/AROM-1 breast cancer cells 185
Compatible osmolytes modulate the response of porcine endothelial cells to hypertonicity and protect them from apoptosis 184
5-benzylidene-hydantoins as new inhibitors of cell proliferation 183
Physicochemical and pharmacokinetic properties of polymeric films loaded with cisplatin for the treatment of malignant pleural mesothelioma 183
Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines 180
5-benzylidene-hydantoin UPR 1024 acts as EGFR inhibitor and induces DNA damage in A549 NSCLC cell line 180
Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification 180
Antiproliferative and proapototic effects of a new combi-molecule on non small cell lung cancer cell lines 179
Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations. 176
Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines 176
Dose-dependent effect of FHIT-inducible expression in Calu-1 lung cancer cell line 175
Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer 175
Left lung allotransplantation in the rabbit. An experimental model for assessment of lung preservation 175
Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion 174
Anti-proliferative effects of copper(II) complexes with hydroxyquinoline-thiosemicarbazone ligands 174
Corrigendum: CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells (Frontiers in Oncology, (2022), 12, (942341), 10.3389/fonc.2022.942341) 174
Intrapleural polymeric devices containing Cisplatin for malignant pleural Mesothelioma in a rat tumor model: a preliminary study. 171
An original application of plasma expanders: heart-lung preservation. 170
SiC/SiO2/M-NP core/shell nanowires functionalized with fluorinated porphyrins 169
Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines 168
Molecular mechanisms underlying the antitumor activity of 3-aminopropanamide irreversible inhibitors of the epidermal growth factor receptor in non-small cell lung cancer 168
CDK4/6 INHIBITORS AS A NEW THERAPEUTIC APPROACH IN MESOTHELIOMA MODELS 167
Attenuated expression of 70kDa heat shock protein in WI-38 human fibroblasts during aging in vitro 167
Effect of specific PI3K/mTOR inhibitors in squamous lung cancer cells carrying PI3K alterations 165
Cell culture studies of polysaccharide films loaded with cisplatin for the loco-regional therapy of malignant pleural mesothelioma 165
Intrapleural adjuvant treatment of mesothelioma : The combination of cisplatin-pemetrexed in rat tumor model 165
Lung mesenchymal cells function as an inductive microenvironment for human lung cancer propagating cells† 164
Interaction between occupational radon exposure and tobacco smoke: a systematic review 162
Critical Issues in Assessing Occupational Exposure to Diesel Dust Exhaust 162
Methodology for the assessment of lung protection. Human pulmonary artery endothelial cell preservation using haemaccel. 161
CDK4/6 inhibitors overcome resistance to osimertinib in NSCLC cell lines independently from resistance mechanisms 161
Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN 161
1929O Soluble PD-L1 and circulating CD8+PD1+ and NK cells enclose a highly prognostic and predictive immune effector score in immunotherapy treated NSCLC patients 160
Meccanismo d’azione di UPR 1024: un nuovo farmaco con attività antiproliferativa in cellule di carcinoma polmonare umano 160
Effects of FGFR1 inhibition on survival, proliferation, and energy metabolism in Non Small Cell Lung Cancer (NSCLC) cell lines 160
Aberrant expression of PTEN in squamous lung cancer cells: molecular analysis and impact on the synergistic combination of the targeted therapy with BKM120 and Defactinib 160
155P Antitumoral efficacy of dual blockade of EGFR signaling by osimertinib in combination with selumetinib or cetuximab in activated EGFR human NSCLC tumor models 159
Anti-proliferative and pro-apoptotic effects of Sorafenib in breast cancer cells in vitro. 159
Gefitinib metabolism by CYP1A1 affects biological responses in NSCLC cell lines. 157
Adaptive cellular response to osmotic stress in pig articular chondrocytes 157
Erlotinib enhances antibody-dependent cellular cytotoxicity of wil-type erlotinib-sensitive NSCLC cell lines 154
Mannich base derivatives as novel EGFR irreversible inhibitors 153
An effective solution for prolonged preservation of cultured human pulmonary artery endothelial cells 152
Dual mechanisms of action of the 5-benzylidene-hydantoin UPR1024 on lung cancer cell lines 152
Drug-induced cellular death dynamics monitored by a highly sensitive organic electrochemical system 152
Anti-proliferative and pro-apoptotic effects of soarfenib in MCF-7/AROM-1 breast cancer cells. 151
Synergistic activity of letrozole and sorafenib on breast cancer cells 150
New MDR1 inhibitors for overcoming multidrug resistance 150
SiO2/SiC core-shell nanowires for nanomedicine applications 150
) Sperimentazione su pneumociti di tipo II per la conservazione del polmone in funzione del trapianto. Soluzioni idroelettrolitiche a confronto. 149
Epidermal Growth Factor Receptor Irreversible Inhibitors: Chemical Exploration of the Cysteine-Trap Portion 149
Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones. (Cavazzoni and Bonelli co-first authors) 149
A new extracellular type solution for lung preservation: "in vitro" comparison with Beltzer, low potassium Dextran and Euro-Collins solutions by means of human lung fibroblasts. 148
Alterazioni della degradazione proteasoma-dipendente nel corso dell'invecchiamento ed effetti delle restrizioni caloriche 148
Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated NSCLC 148
Osmotic regulation of ATA2 mRNA expression and amino acid transport system A activity 148
Identification and tumorigenic role of Mesenchymal Stem Cells from human lung cancer 148
Clinical perspective for irreversible tyrosine kinase inhibitors in cancer 148
Cytocompatible 3C-SiC/SiO2 core shell nanowires for bimodal cancer therapy 147
Combination of EGFR-TKIs and chemotherapy in advanced EGFR mutated NSCLC: review of the literature and future perspectives 147
New strategies to overcome resistance to EGFR tyrosine kinase inhibitors in non small cell lung cancer 146
Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients 146
5'-Untranslated region of heat shock protein 70 mRNA drives translation under hypertonic conditions 146
Alterazioni della degradazione proteasoma-dipendente nel corso dell’invecchiamento ed effetti delle restrizioni caloriche 146
Totale 18.169
Salva come PNG Salva come JPEG
Categoria #
all - tutte 110.991
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 110.991
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.008 0 33 48 65 26 12 141 131 62 76 74 340
2022/20234.288 422 456 285 283 433 470 39 274 1.376 28 170 52
2023/20241.849 88 141 59 50 151 456 135 144 65 96 160 304
2024/20255.776 190 299 369 407 558 621 313 236 784 502 511 986
2025/202612.267 1.114 1.165 1.537 1.116 1.621 664 1.306 378 1.663 916 476 311
2026/2027832 380 452 0 0 0 0 0 0 0 0 0 0
Totale 32.970